Acumen Q2 2026 net loss $32.7M, cash $110.2M; ALTITUDE-AD topline due late 2026

Acumen Pharmaceuticals, Inc.

Net loss $32.7M vs $41.0M in Q2 2025; loss from operations $32.6M.
Cash and equivalents $110.2M at June 30, 2026, down from $128.4M at March 31; funds into early 2027.
R&D expenses $27.8M vs $37.1M prior year on lower ALTITUDE-AD manufacturing and CRO costs.
Expects topline from Phase 2 ALTITUDE-AD (542 participants, 35/50 mg/kg vs placebo) in late 2026.
Nominated EBD candidates ACU301 and ACU401; IND submission targeted mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.